First VA-Led MDMA Trial for Veterans

The Veterans Affairs Department has launched its first direct MDMA trial for veterans, and the study will test a drug long wrapped in promise and doubt.

Quick Take

The trial will study **MDMA-assisted therapy** for veterans with **post-traumatic stress disorder** and **alcohol use disorder**.
Researchers plan to enroll about **80 veterans** at the Providence, Rhode Island, and West Haven, Connecticut sites.
The study uses **identical psychotherapy** with an **active placebo**, not an inert sugar pill.
The Veterans Affairs Department says it will work with the **Food and Drug Administration** and share the data with the agency.

What the new trial is testing

The Veterans Affairs Department says the study will test whether MDMA-assisted therapy can help veterans with severe mental health problems, including post-traumatic stress disorder and alcohol use disorder. The trial is titled “A Randomized Controlled Trial of MDMA-Assisted Therapy for PTSD and Alcohol Use Disorder in U.S. Veterans,” and it is registered on ClinicalTrials.gov as NCT07118839. That registration gives the project a formal public record and lets outside observers track the design.

The trial is being run as a randomized, placebo-controlled study with about 80 participants. Veterans will be recruited from the Providence Veterans Affairs campus and the Veterans Affairs Connecticut Healthcare System in West Haven. The department says the therapy will be delivered in a safe, controlled clinical setting with pharmaceutical-grade drugs and safety rules developed with the Food and Drug Administration. That matters because MDMA research has been slowed by questions about how well earlier studies were blinded.

Why the design matters

The study does not test MDMA as a stand-alone fix. It pairs the drug with structured psychotherapy, which is the same basic model used in earlier psychedelic trials. The comparison group will receive identical psychotherapy plus an active placebo, which is meant to make it harder for patients to guess which treatment they got. That design aims to reduce expectancy bias, one of the main criticisms raised in earlier MDMA reviews.

Even so, the study has limits. The sample is small, and it spans only two sites, so the results may not capture the full range of veteran experience. The trial also focuses on veterans who have already tried and stopped at least one first-line evidence-based PTSD treatment, so it is aimed at treatment-resistant cases rather than the broader PTSD population. It also excludes people with recent serious suicide risk, which means the findings may not apply to the most fragile patients.

Why supporters see it as a major step

Veterans advocacy groups have welcomed the trial as a needed search for new options. That response reflects a real gap in care: many veterans still struggle after standard therapy, and the Veterans Affairs Department has said it wants definitive evidence on psychedelic treatments. The new trial also fits a larger federal push tied to President Donald Trump’s executive order on accelerating medical treatments for serious mental illness. That link will likely keep the study in the political spotlight.

What changed: in May 2026 the VA launched its own clinical trial of MDMA-assisted therapy for PTSD and alcohol use disorder — about 80 veterans, run through VA sites in Providence, RI and West Haven, CT.

— Psychedelic Vets (@PsychedelicVets) June 29, 2026

At the same time, MDMA still faces a hard regulatory road. The Food and Drug Administration rejected prior MDMA approval efforts in 2024 after raising study design concerns, especially around blinding and expectancy bias. That history means positive headlines alone will not settle the debate. The real test will come from the data, the quality of the follow-up analysis, and whether the results are strong enough to satisfy regulators who have already shown they will not move fast without solid proof.

What veterans should watch next

Veterans following the trial should watch three things: who gets enrolled, how well the placebo design works, and whether benefits last after treatment ends. The Veterans Affairs Department says it intends to share the trial data with the Food and Drug Administration, which makes the study more than a local experiment. If the results hold up, the findings could help shape future approvals and future Veterans Affairs research on psychedelic care.

For now, the most important point is simple. The federal government is no longer just talking about psychedelic therapy for veterans; it is testing it in a formal clinical trial. That may help answer long-running questions about MDMA, but it will also expose whether the treatment can clear the same bar that blocked earlier approval efforts. For veterans who have run out of standard options, the stakes are high either way.